Skip to content
Home/Companies/MedTech/Biomodex

Biomodex

MedTech·France·Exited 2023·Held 7yr
Entry
2016
Hold
7yr
Exit
2023

Who owns Biomodex?

Biomodex is a French MedTech company, now owned by Mentice, which acquired it in 2023 from LBO France.

Hand-verified · updated 2026-04-21

Open JSON · CC-BY
LBO France
Investor
LBO France
LBO France Venture · 2016 · VC

Key facts

HQFrance
SectorMedTech
Exit Type
Trade Sale
Buyer
Mentice
Exit Year
2023

More from LBO France Venture

Other portfolio companies in the same fund.

12.5
Active
TMTFrance· 2025
Antidote
Active
HealthTechUK· 2025
Mediaire
Active
HealthTechGermany· 2025
Siteflow
Siteflow
Active
SaaSFrance· 2025
Colpad
Active
HealthcareFrance· 2024
Vestalis
Vestalis
Active
ConsumerFrance· 2023

More PE-backed in MedTech

Comparable medtech deals from other GPs.

Acufocus, Inc.
Exited 2023
The Carlyle GroupUS
to Bausch + Lomb
Adicon Holdings Limited
Active
The Carlyle GroupUS
Aesynt
Exited 2016
Francisco PartnersUS
to Omnicell
Alere Medical, Inc.
Active
TA AssociatesUS
Alma Lasers, Ltd.
Alma Lasers, Ltd.
Active
TA AssociatesIsrael
Amedes Group
Active
General AtlanticGermany

Questions

Who owns Biomodex?

Biomodex is now owned by Mentice, which acquired it in 2023 from LBO France.

When did Mentice acquire Biomodex?

Mentice acquired Biomodex in 2023, buying from LBO France.

Who did Biomodex sell to?

LBO France sold Biomodex to Mentice in 2023 (Trade Sale).

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue